Signals · marvelbiotechnology.com
What just happened at Marvel Biosciences
Last updated
Marvel Biosciences secures funding from 5 Horizons Ventures for Phase I trial of MB-204, aimed at treating autism and related conditions on 2026-04-07. It was reported by globenewswire.com.
The evidence, dated and sourced
- — Funding: Marvel Biosciences secures funding from 5 Horizons Ventures for Phase I trial of MB-204, aimed at treating autism and related conditions.
Press / news → - — Funding: Marvel Biosciences raised $475,699 Seed.
Press / news →
How this is sourced
Every row above links to the document it came from — an SEC filing on EDGAR, or the announcement a publisher ran. Fundz does not paraphrase a source it has not stored, and each row is labelled sec_filing or press_or_news so you can see which you are reading. Funding rounds come from SEC Form D filings and announcements; 8-K events come from the filings themselves. No contact or people data appears here.
Companies with recent events
- CAEPlus — last event 2026-08-18
- NALA Membranes — last event 2026-01-26
- Albatross Energetics — last event 2026-07-01
Get this via API or MCP
The same evidence, as JSON, for your own agents. Quickstart → · MCP endpoint https://api.fundz.net/v1/agent/mcp
curl -s -X POST https://api.fundz.net/v1/agent/why_now \
-H "X-Fundz-Key: $FUNDZ_KEY" -H "Content-Type: application/json" \
-d '{"domain": "marvelbiotechnology.com"}'